Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026Business Wire • 01/27/26
Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/13/26
Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026Business Wire • 01/11/26
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer StudyZacks Investment Research • 01/08/26
Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal CancerBusiness Wire • 01/07/26
Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026Business Wire • 01/06/26
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day TranscriptSeeking Alpha • 12/11/25
Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025Business Wire • 12/03/25
Why Exelixis (EXEL) International Revenue Trends Deserve Your AttentionZacks Investment Research • 11/17/25
Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference TranscriptSeeking Alpha • 11/10/25
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate UpdateBusiness Wire • 11/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc. - EXELPRNewsWire • 10/28/25